

E-ISSN: 2616-4493 P-ISSN: 2616-4485 www.homoeopathicjournal.com IJHS 2024; 8(2): 560-573 Received: 18-04-2024 Accepted: 24-05-2024

**Dr. Mridusmita Bhagawati** Consultant Physician, Bandan Homoeo Clinic, Assam, India

#### Dr. Mridupaban Dutta

Practice of Medicine, Bandan Homoeo Clinic, Assam, India

# Efficacy of *Fucus vesiculosus* Q & thyroidinum 3x in treatment of hypothyroidism

International Journal of Homoeopathic Sciences

## Dr. Mridusmita Bhagawati and Dr. Mridupaban Dutta

### DOI: https://doi.org/10.33545/26164485.2024.v8.i2h.1185

#### Abstract

Hypothyroidism, a prevalent endocrine disorder characterized by insufficient thyroid hormone production, poses significant challenges in conventional medicine due to varying responses to treatment and long-term management issues. Homeopathy, an alternative medical system, offers a holistic approach to addressing hypothyroidism by considering individualized symptoms, emotional states, and overall health of the patient. This article explores the scope of homeopathic treatment for hypothyroidism, emphasizing the principles of individualization and the use of diluted remedies to stimulate the body's innate healing mechanisms. Through a review of clinical studies, case reports, and theoretical frameworks, we analyse the efficacy, safety, and patient outcomes associated with homeopathic interventions. Additionally, the article discusses the potential synergies between homeopathy and conventional therapies, proposing a complementary approach to optimize patient care and improve quality of life for individuals with hypothyroidism.

Keywords: Hypothyroidism, homeopathy, alternative medicine, holistic approach, clinical studies

#### Introduction

The thyroid is a small, butterfly-shaped gland located at the base of the neck, just below the Adam's apple. The thyroid gland makes two main hormones thyroxine  $(T_4)$  and triiodothyronine  $(T_3)$ . These hormones affect every cell in the body. Hypothyroidism happens when the thyroid gland doesn't make enough hormones. It is a condition characterised by an underactive thyroid gland, presenting a significant health concern affecting millions worldwide. Conventional treatments, typically involving synthetic thyroid hormone replacement therapy, have been the conventional way of managing hypothyroidism for decades. However, emerging trends in complementary and alternative medicine have sparked interest in exploring alternative therapeutic modalities, including homoeopathy. In the thyroid disorders found most commonly we encounter the following:

### Hypothyroidism

Hypothyroidism occurs when the thyroid gland is underactive and produces insufficient thyroid hormones. Common causes include Hashimoto's thyroiditis, an autoimmune condition, iodine deficiency, and certain medications. Symptoms of hypothyroidism include fatigue, weight gain, cold intolerance, depression, and slowed heart rate. Diagnosis is typically made through elevated levels of thyroid-stimulating hormone (TSH) and low levels of T<sub>4</sub>. Treatment involves hormone replacement therapy with synthetic thyroxine.

### Hyperthyroidism

Hyperthyroidism is characterised by an overactive thyroid gland that produces excess thyroid hormones. Graves' disease, another autoimmune disorder, is the most common cause. Other causes include thyroid nodules and excessive iodine intake. Symptoms include weight loss, heat intolerance, anxiety, tremors, palpitations, and increased heart rate. Diagnosis involves low TSH levels and elevated  $T_3$  and  $T_4$  levels. Treatments include antithyroid medications, radioactive iodine therapy, and sometimes surgery.

#### Goitre

A goitre is an abnormal enlargement of the thyroid gland, which can occur with both hypoand hyperthyroidism or even in euthyroid (normal functioning) states. It can be caused by iodine deficiency, thyroiditis, and genetic factors.

Corresponding Author: Dr. Mridusmita Bhagawati Consultant Physician, Bandan Homoeo Clinic, Assam, India Symptoms can include visible swelling in the neck, difficulty swallowing or breathing, and a feeling of tightness in the throat. Treatment depends on the underlying cause and may involve iodine supplementation, medications, or surgery.

## Thyroid nodules

Thyroid nodules are lumps that commonly form within the thyroid gland. While most nodules are benign, a small percentage can be cancerous. Causes include iodine deficiency, genetic predisposition, and chronic inflammation of the thyroid. Symptoms are often absent, but larger nodules can cause visible swelling and compressive symptoms. Diagnosis is often made via ultrasound and fineneedle aspiration biopsy. Treatment varies from observation to surgical removal, depending on the nature of the nodule.

## Thyroid cancer

Thyroid cancer, although relatively uncommon, is a serious condition involving malignant growth within the thyroid gland. The main types include papillary, follicular, medullary, and anaplastic thyroid cancer. Risk factors include radiation exposure, family history, and certain genetic mutations. Symptoms might include a lump in the neck, hoarseness, difficulty swallowing, and swollen lymph nodes. Treatment typically involves surgery, radioactive iodine treatment, and sometimes chemotherapy or radiation therapy.

Thyroid disorders encompass a range of conditions that can significantly impact an individual's health. Accurate diagnosis and appropriate treatment are essential for managing these conditions effectively, involving a combination of clinical evaluation, laboratory tests, and imaging studies. Regular monitoring and follow-up are crucial to ensure optimal thyroid function and overall wellbeing of the person.

### Role of homoeopathy in thyroid treatment

Homoeopathy, founded on the principle of "like cures like," operates on the belief that substances causing symptoms in healthy individuals can alleviate similar symptoms when diluted to ultra-low concentrations. Despite scepticism surrounding its efficacy, homoeopathy has gained popularity among individuals seeking holistic and personalised approaches to healthcare.

The management of hypothyroidism with homoeopathy is a topic of growing interest and debate within the medical community. Advocates of homoeopathy propose that its individualised approach, focusing on addressing the underlying imbalances in the body, may offer benefits beyond conventional treatments. It is suggested that homoeopathic remedies, carefully selected based on the patient's unique symptom profile, have the potential to stimulate the body's self-regulatory mechanisms, thereby restoring thyroid function.

This paper aims to provide a comprehensive overview of the current landscape of homoeopathic treatment for hypothyroidism. By examining existing literature, clinical evidence, and theoretical frameworks, we seek to critically evaluate the efficacy, safety, and practical implications of integrating homoeopathy into the management of hypothyroidism. Additionally, we aim to identify gaps in knowledge and outline avenues for future research to enhance our understanding of this alternative therapeutic approach.

### Objective

The aim of the study is to evaluate the usefulness of homoeopathic medicines Fucus vesiculosus Q & Thyroidinum 3x in the treatment of hypothyroidism.

## **Material and Methods**

Total 6 patients of newly diagnosed hypothyroidism including both male and female aged 25 to 55 years were treated on an OPD basis.

Pathological symptoms and physical generals were considered and two drugs Fucus vesiculosus Q & Thyroidinum 3x were prescribed to all the patients to see its efficacy in treating hypothyroidism.

## Consents

Appropriate patient consent forms have been signed by the patients. They have given consent for their images and clinical information to be used in the article. The patients understand that their names and initials will not be published and their identity will be concealed as best as is possible.

## Inclusion criteria

Patients of age groups 25-55 yrs. both sexes, and acute cases were included in the study.

### Exclusion criteria

Cases of hypothyroidism with co-morbidities were excluded from the study.

Sr. No.	Case no	Age/ Gender	TSH level at the starting of treatment/ uIU/mL	Chief complaints/ symptoms/ concomitants	TSH levels after 3 months of treatment/ uIU/mL	TSH levels after 6 months treatment uIU/mL	Results
1.	Case A	34/M	10.30	Dry skin, lethargy	5.11	3.55	No lethargy and skin dryness
2.	Case B	47/F	32.78	Hair fall, dry skin, constipation	3.36	3.05	Very minimum hair fall & regular bowel movements.
3.	Case C	44/F	15.37	Joint pains, thirst for cold water	2.79	4.50	Free from joint pains.
4.	Case D	33/F	27.12	Menstrual irregularities, hair fall	7.42	2.78	Menstruation regular & reduced hair fall.
5.	Case E	38/F	6.79	Dry skin, constipation, weight gain	3.9	4.2	Regular bowels, skin better, weight is under control.
6.	Case F	45/F	9.27	Generalised weakness	3.9	3.06	Regular bowels, skin better, weight is under control.

### **Table 1:** Representing symptoms and thyroid levels before and after

\*TSH normal range: 3.5 - 5.50 uIU/mL.

#### Results

All the cases were treated with Fucus V. Q & Thyroidinum 3x and the thyroid levels showed considerable improvement

over 3 - 6 months and the general symptoms of the patients were also relieved along with.

Publicer Marcin		1 11	RM - A	Gate .	15/9/23
		h.Kr.			
Ins. No.	BERY C	the second s		Hed NO.	
TEST	FINDINGS	NORMAL RANGE	TEST Blood Sugar (Random)	FINDINGS mg/dl	NORMAL RANGE
1238	mai Adrin	F : 0 - 20 mm	Blood Sugar (Finsting)	nig/d	'4 - 110 mg/df
Heamoglabie	g/d)	M : 14.6 - 17.8 g/dl F : 12.1 - 15.9 g/dl	(13 Hood Sugar ()'?') (13 Hirs after food) Urma	there are a constant of the second se	(/pto 140 mg/d) (8 - 35 mg/d)
Total WBC	( cu, mun	4000 + 11000/ au mm	Creatinine	mgidi	4: 0.70 - 1.30 mg/dl
Total RBC	million / cu mm		Total Cholesterol	mg/dl	1:0.6 - 1.1 mg/dl 1 - 200 mg/dl
		F : 3.8 - 5.5 million / eu nur	Triglycerule	(mg/d)	10 - 160 mg/dl
Platalei Count		1.5 - 4.5 Likh / tu mm	LDL Cholesterol	B'gen D'gen	5.3 - 79.5 mg/dl -130 mg/dl
BT.	Min. Swa	the stag rando stag of a low or the strength star water and	VLDL Cholesterol	(ng/d)	- 32 march
CT .	Min	Concerns and the local data and the	Uele Acid	mg/dl	16:3.3 + 7.0 xig/dl 2.4 - 5.7 mg/dl
ASC	ou mm.	40 + 440 / ett men	SOUT (AST)	D.V.L.	0-35.01U/L
PBS FOR MF			ABalloe Phosphatase	RVL.	0- 45.0 ILV1. ADULT: 53 - 128 ILVL
	35	40 - 75 35	Auxilia Pausposiasi		CHILD: 210-\$10 R.M.
Polyenorph		20 - 40 %	CCT Tour Disable	light. ing/d	0+55 R.M. 3.0-2.0 mg/dk
Monocytes		2-330	Tatal Bilirubia Direct Bilirubia	माङ्गुरा लाङ्ग्या	1-0.2 mg/di
Basochi		1.6%	Indirest Dilirahin	marif.	(人) 2 - 使, 使 (1) (2) (2)
PEN		the second	Total Protein Albumin	g/dl g/dl	64-83\$9 13-82\$9
PCV	74	M. 42 - 53 % 7 : 36 - 46 %	Giobulin	100 B	13-3344
MCV	w/E3	76 - 99 une3	Amylate	1936	12-101-1
MCHC	PI	17 - 12 PS 10 - 33 %	Lipase Sedium (Na)	IUL nimolil.	115 - 145 m mol/L
Catalogue and the first of the	61	32×33.78	Potsastum (K)	05 t300 L	13-53 m.moVL
HIVIAT	een Zaanna		Chioride (CD	m.mol/L nug/di	38 - 107 m moVL 96 - 10.2 ma/dl
TRAAg To			Ca2+	100,45	Toy - I and the second
WDRL/TPH	Test.		(C)	195	
ASI3 Tion	55 1893	(1-200 R.Ver)	ABO		
CAP		15 gm 0 & - 5	Rh		
Q 3.4 5:00		0 - 20 6 R.Sml	73	1875- upm1	0.6 - 1.81 ng/ml. 3.61 - 12.45 µg/m2.
Typhi Dot	ariges Terri		1381	5.11 JEME	0.35-5.30 µlt/ml.
	ig 6		FB	PataL	2.3 - 4.2 pg/mL 5.89 + 1.76 ag/dL
Dengue Ter	4 Ag 1		F14	ngʻil	Normal < 5.7%
	2 M		ffbAlc Test	15	Pre Diabetes 5.7 - 6,4% Diabetes > 6.5%
	Tabe/ Slide Method	p .	MONTOUX TEST (	ST.U.107.U.)	
(1919111) (C) 1.17	1:40 1:30	1:160 1:320			
HURGEL W		and the second second second second second second			
all and the					
PAP					

No.
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Protection in the Pariet Kurmer Bhagat 34 m M. And Ho. 2021 Allocations and the protection of the pr
Apple 1         Apple 2         Apple 2 <t< td=""></t<>
Apple 1         Apple 2         Apple 2 <t< td=""></t<>
Apple 1         Apple 2         Apple 2 <t< td=""></t<>
Apple 1         Apple 2         Apple 2 <t< td=""></t<>
Processing of the second sec
Processing of the second sec
Prod         Interface         Int
Proc         Description         1 (number of a 10 % for a result         manual (number of a 10 % for a result)         manual (number of
Photo         A function         A function </td
Control         Control <t< td=""></t<>
Industry
Industry
Industry
Industry
Non-construction         201
1     1
1     1
Internation     Base 1     5     6       And Mark     And Mark     And Mark     Mark     Mark       And Mark     And Mark     And Mark     Mark     Mark       And Mark     And Mark     And Mark     Mark     Mark       And Mark     And Mark     Mark     Mark     Mark       And Mark     Mark     Mark     Mark     Mark
No.     No.     No.     No.     No.     No.       No.     No.     No.
And With State     and With State     and With State       Market State     Market State     Market State
1     1
1     1
Intervision         Construction         Construction </td
Intervision         Construction         Construction </td
Litty Rui         Ruid         S. 3 - 10.3 mm/d           Virtui / roma Yout         0 - 20 mm/d         1 - 0.20           ASO 'If re         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20 mm/d           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20 mm/d           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20 mm/d           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20 mm/d           1 - 0.20 mm/d         0 - 0.20 mm/d         1 - 0.20 mm/d
Class         Clas         Class         Class <thc< td=""></thc<>
1     1
1         2.4.0 mplat           1         2.0.0 mplat           1
1976 17 Astly m 2001         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           1976 17 Astly m 2001         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           1976 17 Astly m 2001         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           10 Designe Digit         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           10 Designe Digit         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           10 Designe Digit         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           10 Designe Digit         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           10 Designe Digit         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001           10 Designe Digit         100 Astly m 2001         100 Astly m 2001         100 Astly m 2001
Ig 0         Ig 0 <th< td=""></th<>
1 Gangar Dist         123-12 No. 1         123-12 No. 1         123-12 No. 1           1 Gangar Dist         100-1         100-1         100-1         100-1           1 gangar Dist         100-1         100-1         100-1         100-1
- 7世代目 - 7世代日 - 7
4470 4 minutes and minutes a And minutes and minutes a
1 10 1 10 10 10 10 10 10 10 10 10 10 10
Lochers > 5-51
[1] WARDER (DED) 2003 14000] MCMTOLIC DEF (STUDIETU)
The second se
그는 것 같은 것 같
[An Tarizative
John Tanizaithea Zithningidi

	1	C	SE-B			
~	12	· -		1. 1		
11.	C		भी: नि. आदर्श अन् DDEL HOSPIT ORATORY RE St 37	Punner, Benter AL, BELTOI PORT (Dept. ORM - A	ग, गुवाहाटी A, GUWAI of patholog	- 22 IATI - 22 Sy)
					Dot	13 6 23
i s	Patient Nav	ne Mina	lalie k dar	HALDI	1	1.7
	TEST	FINDINGS	NORMAL RANGE	TEST Nood Senar (Rander)	VINDINGS	Ward No.
1. 7	Hetenoglahin	g/d]	F <sup>-</sup> : 0 - 20 mm M : 14.6 - 17.8 g/dl	Blood Sugar (Fasting) Elecod Sugar (PP) (12 Hirs after food)	ing/dl ing/dl	74-170mg/dl
1	Total WBC	/ cu unn	F: 12.1 - 15.9 g/dl 4000 - 11000/ su mm	Oren Creatinine	0'9. mg/dl	
1	Total RBC	miliou / ou mm	M i 4.6 - 6.1 million / cu mu F : 3.8 • 5.5 million / cu per	Total Cholestorol	198 mg/dl	Fro.6-1.1-min/di
1	Platelet Count		LIS -4.5 Lakh / cu min	HDL Cholesterol	129 mg/dl	1 4G - L60 mat/d1
87	CT		/	LDL Chalastarol	1221 mar/dl	<1.30 ine/dl
/	ABC		40 - 440 / cu mm	Uric Aold	ng/dl	84:3.5-7.0 mg/d
11	PBS FOR MP		HU - HOU / CU HICH	YOOT (AST)	27 104	F:3.4-5.7 mg/dl
1	- Jaine		11	Alkaline Phosphatase	1 3 4 1924	1 0 - d(1.0 R)/L
1	Polymorph Lymphozytes		7 40 - 75 %	GGT	1	ADULT: 53 - 129 IUM; CHILD: 210 - 810 R.M.
1.	Monocytes	. 96	20-40%	Potal Bilirabin	10.9 mg/dl	0-33 JU/L 0.0-2.0 mp/d
1	Besophil		1-696	Divect Etilirubin Indirect Bilirubin	h mg/dl	0-0.2 mg/ol
	PCV I	951	M: 42 - 52 %	Tetal Protein	7.6 g/ci	6.4 - 8.3 g/dl
1.00	MCV		F: 36 - 46 %	Clobulla	1 3 9 g/dl	3.5-5.2 g/dl
1	MCH	Emn gq	76 - 96 um3	Linnae	IUA.	22-50 HML
1	MCHC ·	96	30-35%	Sodhung (Na)	IO/L, mmol/L	0.0-60.010//, 135-145 mmo//,
4	LI HIVI & 2 TA	und I	10.V	Porassitum (K) Citiorida (CI)	Minou/L atmot/L	3.3-3.3 mmol/L 98+107 mmol/L
	HCV Test	· 1 ·····	- Section -	P. Time (T)	tng/dl	86 - 10.2 mg/di
	UVDRL/TPHA			(C)	4 300 Fed	1. T. T.
. 4	ASO Tibe	219	0-200 IU/ml	ADO INR	1	
1	RA factor	I monthly and	0-20.0121/1	TJ.	nom	0.6-1.61 ag/mL
1	Typht Dot Ig			TA AGH	un polint	5.01 - 12.45 µg/mL
	D Dengue Tast	G :	milein management of the second	FI3	pg/mL	0.35-5.50 p2U/mL -1
8. A.	· NS,A	va :		P14.	ng/dL	0.89 - 1.76 ng/dL Monnal < 3.7%
+ 1	is and the second of Ig.			MbA1a Tout	96	Pre Dinbetes 5.7-6.455 Diabetes > 6.5%
3	D Widal Dest (D	abo/Silds Methoda		MONTOUX TEST (83	UJIOT.U.)	
1	111RE 1:20	1:40 1:80 1:	6011:320		药	
	"AH"		1			the second second
2.1	"AH"			And the second		
	PBSSTUDY:					· 42
8.			State - State	1. C		2
10 a	· (2)		44		ST R COMP	, Mr
1.1	· 2. (	- 81 -	1			Mar.
ан,	133.	1.5	-1) 		1	ditter-
1	W. S.		india.	205- 6 19	172	
*	N/m	10 al	441		13 C 1 C 1 C 1 C 1 C 1 C 1 C 1 C 1 C 1 C	13.
	Lab. Technician		[新] · · · · ·	1 20 1 3		Reining
	生	Se sel	Set of the sector			Partegrant

International Journal of Homoeopathic Sciences

	LABO	RATORY REI	L, BELTOLA, PORT (Dept. of		
	5	188 FC	DRM - A	Date	6/10/23
Regd: No	Char	noto Gha	sl	Are 4	4 sex P
				and the second se	Ward No.
Ins. No	1236	Hospt. No		to the ville of	11-11
TEST	FINDINGS	NORMAL RANGE	TEST		NORMAL RANGE
ESR	mm AEFH	M:0-10 mm F:0-20 mm	Abod Sugar (Randors) Blood Sugar (Pasting)	TTOP/CH	74-110mg/dl
Heemoglobin	8/di	M: 14.6 - 17.8 g/dl	Bined Sugar (PP) (11 Hen after fond)	and the second second	Upto 149 mg/dl
		F: 12.1 - 15.9 g/dl	Une	ma/dl mg/dl	18-35 mg/di ME 0.70-1.30 mg/di
Total WBC	the second se	4000 - 11000/ cu mm	Creatinine		P:0.6-1.1 mg/tt
Total RBC	million / cu mm	M:4.6-6.1 milion/cu.ms F:3.8-5.5 milion/cu.ms	Total Cholasterol Triglyceride		6-200 mg/tl 40-160 mg/tl
Platelet Count	Lakh / cu mm	1.5 -4.5 Lakh / cu mun .	HDL Contentaret	myd	35.3 - 79.5 mg/dl <130 mg/dl
BT	and the second damage in the second damage is a second damage in the second damage is a second damage in the second damage is a se	2-7min	LDL Cholesterol VLDL Cholesterol	me/di	7+32 mg/di
cr	successful the second s	5-10 min	Unie Acid	mg/cl	M:3.5-7.0 mg/dl P:2.4-5.7 mg/dl
ABC	/cu mm	40 - 440 / cu mm	SCOT (AST)		0-35.0 ILVL
PBS FOR MP			Alkaline Phosphatase	IUA.	ADULT: 53 - 128 IUAL
Polymarph	. %		Gar	JUL	CHILD:210-819 R.M.
Lymphocytes	**		Total Billeubin		0.0-2.0 mg/di
Honocytes Bosinophil	*	1-6%	Direct Billrabin Diedrect Billrabin	English.	0.2-0.5 mm
Besophil		the second s	Total Protein	Real Real	6A-13 g/di 3.5-52 g/di
PCV	*	F: 36 - 46 %	Giotedia		1.3-3.5 g/di 22-50 IU/L
MCV	um]		Anylase	TLIC	0.0-60.9 IUAL
MCHC	ę.	30-35%	Bodium (Na) Potasahan (S)		135-145 mmol/L 33-53 mmol/L
HIVI 42	Test		Chloride (CI)	mmel/L	98-107 mmol/L 8_6-10.2 mg/dl
HBa Ag Te			P. Time (T)		
U HCV Det			INR INR	A BEA	-
ASOTHE		0-200 IL/m 0-6.0 mg/dl	ABO /	0 rective	
BA factor	, t	0-20.0 IU/m	1 73	ngmi	0.6-1.81 mm/mL 5.01-12.45 yg/mL
	atigen Test :		- 14 	2.79 400	0.35-3.50 juli Jimi.
Typhi Dot	Ig G :		FB	· pg/mL	23-42 pm/mL
Desgue Te			FIA	ng/dL	NOX10181 < 3.776
	IgM :		HhAieTest	56	Pre Diabetes 3.7-6.4
	ig0 :		MONTOUX TEST (5	TU/IOTEL)	
Widel Test	(Tube/Side Metho 0 11:40   1:80	1:160 1:320			
"0"			-		
"H" "AH"			•))		
"BH"			and the second second		i
PBS STUDY :					1.0
81			24		
12.0		1 × 1			
					5855

~ 565 ~

International Journal of Homoeopathic Sciences

Read No.		ODEL HOSPIT ORATORY RI	W ANALL CA		
Patient Nam	mimak	shi Das		Da	ate :17/4/23
Ine No	ae				
The second	ETA TE CONTRACTO	2. J. Hospt. N	0	Bed No	Word No.
TEST	FINDINGS	NORMAL RANGE	1、痛痛に認定的ない	BIO-CHEMIC	NONENSTREESTING
ESR	1 O CHUN AEFH	M:0-10 mm	TEST Blood Sugar (Random	FINDINGS	NORMAL RAN
Heamoglobin	100	F : 0 - 20 mm	Blood Spear (Fasting)	mg/i	dl 74-150 mg/dl
	. g/dį	M: 14.6 - 17.8 g/dl F: 12.1 - 15.9 g/dl	Blood Sugar (PP) (12 Hrs after food)	mg/c	1 Upto 140 mg/dl
Total WBC	/ cu mm	4000 - 11000/ cu mm	Creatinine	mg/c	1 18-55 mg/di
Total RBC	milion / cu mm	M:4.6-6.1 million / cu m		mg/d	M:0.70 - L30 moldl
Platelet Count	Table (	F:3.8-5.5 million / cu mr	Total Cholesterol	mg/d	F: 0.6 - 1.1 mg/dl
		1.5 - 4.5 Lakh / cu mm .	HDL Cholesterol	mg/d	40-160 mg/dl 35.3-79.5 mg/dl
define the second se		2-7 min	LDL Cholesterol VLDL Cholesterol	mg/d	<130 mg/dl
AEC		5-10 min	Uric Acid	mg/d mg/d	7-32 mg/di
PBS FOR MP	/ou mm	40 - 440 / cu mm	SGOT (AST)	0	F: 2.4-5.7 mm/dl
DEC		10	SGPT (ALT)	1 IUI	0-35.0 IU/L
Polymorph	~ %	40 - 75 %	Alkaline Phosphatase	· IU/L	ADULT: 53 - 128 11/1
Lymphocytes Monocytes	· · · · · ·	20-40%	GGT	IUIL	CHILD:210-810 IU/L
Eosinophil	%	2-8%	Total Bilirubin	mg/di	0.0-2.0mg/dl
Basonta		1-6%	Indurect Bilirubin	mg/dl	0-0.2 mg/dl
PCV	%	M: 42 - 52 %	Total Protein	mg/d1 g/d1	0.2-0.8me/di 6.4-8.3 g/di
	10	F: 36 - 46 %	Albumin	g/dl	3.5-5.2 g/di
MCV MCH	<u>µm3</u>	76 - 96 um3	Amylase	g/dl IU/L	1.5-3.5 g/dl
MCHC	Pg %	27 - 32 pg 30 - 35 %	Lipase	IUL	22-80 HJ/L 0.0-60:0 HJ/L
OTHERS		30-33%	Sodium (Na) Potassium (K)	m mol/L	135-145 mmol/L
HIVI& 2 Tes	rt :		Chioride (CI)	D mmol/L	3.5 - 5.3 m mol/L 98 - 107 m mol/L
HBs Ag Test	· · · ·		P.Time (T)	N/A mg/dl	86 - 10.2 mg/di
VDRL/TPHA	Test :		(C)	500 800	領
ASO Titre	2	0-200 Ht/ml	INR ABO		12.5
Z RA factor	24.0	0-6.0 mg/dl	Rh		
PF& PV Autig	en lest:		13 14	ng/mL	0.6-1.81 ng/mL
T vyburnot 18 v	· · · · · · · · · · · · · · · · · · ·		TSH	Hg/mL	5.01 - 12.45 µg/mL
Ig G Dengue Test			FT3	pg/mL	0.35-5.50 µlU/mL
· NS,Ag		/	FT4	ng/dL	0.89 - 1.76 ng/dL
Ig M	f :	4.65	HbA1e Test	96	Normal < 5.7% Pre Diaboten 5.7 - 6.4%
] Widal Test (Tut			MONTOUX TEST (ST	LIGOTUS	Diabetes > 6.5%
TIRE 1:20 11	:40 1:80 1:1	6011-3201			101
0" H"		- ANDEN			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
AH"			s		1. J. 191
BHT'					4
BS STUDY :			-		
		4. <u>(</u> . 1997)	1		
8 g - 18			영국 비행하는 이상		
5 ×	., i M		N		5. JE
56 C					100 H
					A 19.3
	- AGAN	the state of the s			1.1.1

Fin	क. रा.	बी. नि. आदर्श ODEL HOSPI ORATORY R	and another		
	E.S.I.C. M	ODEL HOSPI	TAL. BELTO	तला, गुवाहात	मी - 22
	LAE	BORATORY R	EPORT (Dep	t. of pathol	HATI - 22
- ENGLIS INC.	And the second se	0.		Contract of the second s	
Patient Nam	- his	a bel		D	hate: DJ 6/23
Ins. No	22	21	Day	Age	34 Sex 12
Frank Andrew Y	THAT BURNEY	IGALENEST	No	Bed No.	3 4 Sex 12
and the second of the second s	FINDINGS	NORMALRANG		HOMMIN	Wild No.
ESR	mm AEFH	M:0-10 mm	E TEST Blood Sugar (Rarsh	FINDINGS	NORMAL PANOT
Heamoglobin	inter in	F : 0 - 20 mm	Blood Spaar (Fastin	The second secon	/dl 74 - 150 mg/dl /dl 74 - 110 mg/dl
-	Brui	M : 14.6 - 17.8 g/dl F : 12.1 - 15.9 g/dl	Bipod Sugar (PP) (11 Hrs after food)	mg	dl Upto 140 mg/dl
Total WBC	/ cu mm	4000 ~ 11000/ cu mm	Creatinine	IDg/	
- AND AND A	milion / cu mm	M:4.6-6.1 million/cum F:3.8-5.5 million/cum		ma	df M: 0.70 - 1.30 mg/dl F: 0.6 - 1.1 ma/dl
Platelet Count	Lakh / cu mm	1.5 - 4.5 Latch / cu mm	Triglyceride	mg/	di 0-200 mg/di ii 40-160 mg/di
Br -	Min	2 -7 min	HDL Cholesterol	ma/c	1 353,70 Smald
AEC -	MinSecs		VLDL Cholesterol	mg/d	1 <130 mg/dl 1 7-32 mg/dl
PBS FOR MP	/cu mm	40440 / cu mm		nig/d	4 M:3.5 - 7.0 mg/di
TORE ME	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		SOOT(AST)	IUA	F:2.4-5.7 mg/dl
Polymorph	- %	40. 54.54	Alkaline Phosphata		0-45.0 11.14
Lyniphocytes		40 - 75 %	GGT		CHILD:210-510101, 0-5510/L
Eosinophil	9% 96	2-8%	Total Billimbin Direct Billimbin	mg/dl	0.0-2.0 model
[Basophil ]	56	0-1%	Indirect Billrabin	mg/dl	0-0.2 mg/dl 0.2-0.8 mg/dl
Electron of the		M: 42 - 52 %	Albumin	g/dJ	6.4-83 e/dl
MCH	um3	F: 36 - 46 % 76 - 96 µm3	Globutin	#/d3	3.5-52 #/dl
MCHC	P8	27 - 32 pg 30 - 35 %	Lipase	ILVL ILVL	22-501U/L
HIV 1 & 2 Test	1		Sodium (Na) Potassium (K)	mmol/L	135-145 mmol/
HEs Ag Test		-	Chloride (CI) Ca2+	In mol/L	3.5-5.3 m.mol/L. 98-107 m.mol/L.
U HCV Test			P. Time (T)	mp/di see	8.6-10.2 mg/dl
ASO Titre	.I	0-200 IU/ml	(C) INR	500	
RA factor		0-6.0 mg/di	ABO Rb		
DF& PV Antigen Typhi Dut Ig M	Test :	0-20.0 IU/m		ng/mL	0.6 - 1.81 ng/taL
lg G	-		TSH	7.0 µg/mL 7.92 µll.1/mL	5.01 - 12.45 µg/mL 0.35 - 5.50 µIU/mL
Dengue Test NS,Ag		1	FT3 FT4	pg/mL	2.3-4.2 pg/mL
Ig M	1		HbA1e Test		0.89 - 1.76 ng/dL Normal < 5.7%
Ig O			the second sector		Pre Diabetes 5.7-6.4% Diabetes > 6.5%
Within Test (hube/	58de Method)	:	MONTOUX TEST (5 T.	U/IOTU.)	
-H					
"AH"		1 1 1 1	In Section 2		
OH"		1			
PRSSTUDY:		and the second			
the street -	10 M		ACCOUNTS IN THE	a con guilt	and the
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			Section of	1357 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
12	4	1			
	and the state			the set	and the second
		where and the	and the same		
W. Technician	1	and the state of		A DATA STATE	
	Contract parts of	act. The	g. Tames 1 24		Pathopgist
the second second	and the second	Trad Harris	a service and an		Can

International Journal of Homoeopathic Sciences

Patient Name         Bit With         Taluwday         Age         2.8         Sex           Ins. No.         Bed No.         Ward No.           TEST         FINDINGS         NORMAL RANGE           SSR         mm AEPI M. : 0.10 mm         FINDINGS         Ward No.           Hegmoglobin         g/dl         M.: 14.6 - 17.8 g/dl         FINDINGS         MORMAL RANGE           Bagoglobin         g/dl         M.: 14.6 - 17.8 g/dl         FINDINGS         MORMAL RANGE           Test         FINDINGS         MORMAL RANGE         Bit God Super (Parting)         mg/dl         M-: 130 mg/dl           Mage         // cu mn         4000 - 11000 <sup>r</sup> cu mn         FINDINGS         MORMAL RANGE           Test         Mage Super SupeS	Patient Name         District         Taluceday         Age         Sex           Ins. No.         Boll No.         Boll No.         Ward No.           TEST         FINDINGS         NORMAL RANGE           ESR         mm AEFH         M: 0 - 10 ma           Biod Stagr(Bachar)         Y (mg/dl         No.           Hagnoglobin         g/dl         M: 14.6 - 17.8 g/dl           Ins. No.         ////////////////////////////////////		LAD	ORATORY REP 5922 FC	PORT (Dept. o DRM - A	f pathology	0/0/12
Patient Name         Age         <	Patient Name         Age         Age <t< th=""><th>Regd: No</th><th></th><th>SICC</th><th></th><th>Date</th><th>31822</th></t<>	Regd: No		SICC		Date	31822
Ins. No.       Bed No.       Ward No.         TEST FINDINGS NORMAL RANGE         SR       mm AEFH M: 0-10 mm       Finding M: 14.6.17.8 g/dl         Finding M: 14.6.17.8 g/dl       Finding M: 14.6.17.8 g/dl       Finding M: 14.6.17.8 g/dl         Jeanoglobin       g/dt       M: 14.6.17.8 g/dl       Mice Same Charles M: SAME M: S	Ins. No.       Bed No.       Ward No.         TEST       FINDINGS       NORMAL RANGE         TEST       FINDINGS       NORMAL RANGE         TEST       mm AEFH       MI : 0 - 10 mm         Hagnoglobin       g/d       M: 44.5 - 17.8 g/d         F: 12.1 - 15.9 g/d       F: 12.1 - 15.9 g/d         Total WBC       / cu mm       M: 64.6 - 61. million / cu mm         Total WBC       / cu mm 4000 - 11000/ cu mm       M: 64.6 - 61. million / cu mm         Total RBC       million / cu mm       M. 44.6 - 61. million / cu mm         Total RBC       million / cu mm       M. 44.6 - 61. million / cu mm         Total RBC       ////////////////////////////////////	Patient Nam	- 11	sinita Tal	ukday	in 3	8 en F
Intervention of the second sec	TEST         FINDLINGS         NORMAL RANGE           BSR         mm AEFH         M : 0 - 10 mm           Hagmoglobin         g/di         M : 1.4.5 - 17.8 g/di           Total WBC         / cu mm         4000 - 110000/ cu mm           Total WBC         / cu mm         4000 - 110000/ cu mm           Total WBC         / cu mm         M : 4.4.5 - 17.8 g/di           Total WBC         / cu mm         M : 4.4.5 - 17.8 g/di           Total WBC         / cu mm         M : 4.4.5 - 17.8 g/di           Total WBC         / cu mm         M : 4.4.5 - 6.1 milion / cu mm           Total WBC         / cu mm         M : 4.5 - 6.5 mg/di           Total RBC         milion / cu mm         M : 4.5 - 6.5 mg/di           Total RBC         milion / cu mm         M : 4.5 - 6.5 mg/di           Total RBC         milion / cu mm         Sort (A.17)           Total RBC         ////////////////////////////////////		\$712.				
TEST         FINDINGS         NORMAL RANGE           ESR         mm AEPH         M: 0 - 10 mm         BiodSuger(Bardou)         mgd(1         M - 130 ngd(1           Heamoglobin         g(d         M: 1.4.5 - 17.8 g/d1         BiodSuger(Bardou)         mgd(1         M - 130 ng/d1           IdexolSuger(Candou)         g(d)         M: 1.4.5 - 17.8 g/d1         BiodSuger(Candou)         mgd(1         W - 130 ng/d1           Cond         WBC         / cu mm         M - 000 - 11000/ cu mm         mgd(1         W - 7.5 ng/d1         Creatinine         mgd(1         0.2.6. 1,1 mg/d1           Total RBC         million / cu mm         M + 4.6 - 6.1 million / cu mm         Total Cholasterol         mgd(1         0.2.6. ng/d1         0.2.6. ng/d1           Total RBC         million / cu mm         15 - 45 Lukh / cu mm         Total Cholasterol         mgd(1         0.2.0 mg/d1         0.2.0 mg/d1           Total RBC         ////////////////////////////////////	TEST         FINDINGS         NORMAL RANGE           ESR         mm AEFH         M: 0 - 10 mm         Eye and Sugr@Bachay $V_{mg/dl}$ More Mall RAL RANGE           Biod Sugr@Bachay         mg/dl         M: 14.6 - 17.8 g/dl         File - 200 mm         Biod Sugr@Bachay         mg/dl         M- 150 mg/dl           Heamoglobin         g/dl         M: 14.6 - 17.8 g/dl         Biod Sugr@Bachay         mg/dl         M- 150 mg/dl           Dotal WBC         / eu nm         400 - 11000 eu nm         Biod Sugr@Charbay         mg/dl         More Mall RAC           Otal WBC         / eu nm         1.5 4.5 a.8 /s.5 millon / eu nm         Tradyceride         mg/dl         More Mall RAC           Otal RBC         mlion / eu nm         F.5.4 - 5.5 millon / eu nm         Tradyceride         mg/dl         More Mall RAC           T		57176		and the second se		and the second se
ESR         mm AEFH         No 10 mm           Hegmoglobin         g/dl         H. 14.6 - 17.8 g/dl         Hegod Soger (Pandom)         J. C. y.         mg/dl         H. 116.0 - 17.8 g/dl           Hegmoglobin         g/dl         M. 14.6 - 17.8 g/dl         Higod Soger (Pandom)         J. C. y.         mg/dl         H. 110 mg/dl           Total WBC         / cu mm         M. 14.6 - 17.8 g/dl         Ura         mg/dl         H. 100 mg/dl           Total RBC         milion / cu mm         M. 4.5.7.5 million / cu mm         Total Cholasterol         mg/dl         A - 150 mg/dl           Plastelet Count         Lakh / cu mm         F. 3.6 - 5.5 million / cu mm         Total Cholasterol         mg/dl         A - 160 mg/dl           T        MInSecs         2 - 7 min         Total Cholasterol         mg/dl         H. 3.5.7 9.5 mg/dl           TDL Cholasterol         mg/dl         M. 4.5.7.5 mg/dl         HDC. Cholasterol         mg/dl         H. 4.5.20 mg/dl           PBS FOR MP         SOOT (AST)         IL/L         O - 4.50 mg/dl         HDC. Cholasterol         mg/dl         H. 4.5.20 mg/dl           VDRUCTD         KCV         %         4.2 - 8 %         Total Bilinvbin         mg/dl         G 5.51 mg/dl           Sootrice         %         2 - 4 5 %<	ESR         mm AEFH         H: 0 - 10 man           Hagmoglobin         g(d)         F: 0 - 20 mm         Blood Stage (Packag)         mg/d1         74 - 150 mg/d1           Hagmoglobin         g(d)         M: 14.6 - 17.8 g/d1         Ma - 16.0 mg/d1         74 - 150 mg/d1           Total WBC         / cu mm         Advantation         mg/d1         Ma - 16.0 mg/d1         74 - 150 mg/d1           Total WBC         / cu mm         Advantation         mg/d1         Ma - 16.0 mg/d1         74 - 150 mg/d1           Total RBC         mllion / cu mm         Ma - 17.8 g/d1         Total Cholanterol         mg/d1         Ma - 0.70 - 1.30 mg/d1           Total RBC         mllion / cu mm         Ma - 4.5 - 5 millon / cu mm         Total Cholanterol         mg/d1         Ma - 0.70 mg/d1           T        Min         Secs 2 - 7 min         Total Cholanterol         mg/d1         Ma - 37.7 mg/d1           TDC Cholanterol         mg/d1         Ma - 75.5 for mg/d1         Ma - 53.0 mg/d1         Ma - 53.0 mg/d1           YDMorph         54         40 - 75.5 for mg/d1         Ma - 440 / cu mm         Ma - 57.0 mg/d1           YDMorph         54         20 - 40.5 for Mg/d1         Ma - 53.0 mg/d1         Ma - 53.0 mg/d1           YDMorph         54         20 - 40.5 for Mg/d1 </th <th></th> <th>and the second sec</th> <th></th> <th>Name of Concession, Name of Street, or other</th> <th></th> <th></th>		and the second sec		Name of Concession, Name of Street, or other		
Hagmoglobin         F: 0-20 mm         Altest Sign (Parking)         mg/dl         74-110 mg/dl           Hagmoglobin         g/dl         M: 14.6 - 17.8 g/dl         The star food)         mg/dl         74-110 mg/dl           Datal WBC         / cu mm         4000 - 11000/ cu mm         mg/dl         18-55 mg/dl         The star food)         mg/dl         76-70-130 mg/dl           Total WBC         / cu mm         Mich A - 61 millon / cu mm         The A - 61 millon / cu mm         The A - 61 millon / cu mm         The A - 61 mg/dl         76-70-130 mg/dl         The A - 60 mg/dl         The A - 60 mg/dl         76-70-130 mg/dl         76-70-130 mg/dl         76-75 mg/dl         76-75 mg/dl         77-32 mg/dl	Hegmoglobin         F: 0-20 mm         Hegmoglobin         mgdl         74-110 mgdl           Hegmoglobin         g/dl         M: 14.6 - 6.17.8 g/dl         Histod Suger (PP)         mgdl         Upto 140 mg/dl         Upto 140 mg/dl           Cotal WBC         / cu mm         4000 + 11000/ cu mm         mgdl         No.70 - 130 mg/dl         R-55 mg/dl           Cotal WBC         / cu mm         4000 + 11000/ cu mm         mgdl         No.70 - 130 mg/dl         R-70 - 130 mg/dl           Total Cholasterol         mgdl         M: 6.6 - 6.1 millon / cu mm         Total Cholasterol         mgdl         P.06 - 1.1 mg/dl           Min         Sec 2 - 7 min         Total Cholasterol         mg/dl         7-32 mg/dl         HDJ. Cholasterol         mg/dl         7-35 mg/dl           T						
Hasmoglobin       g/dl       M: 14.6 - 17.8 g/dl       Bicod Stage (PP)       mg/dl       Upto 140 mg/dl         Dotal WBC       / cu mm       4000 - 11000 / cu mm       mg/dl       18 - 55 mg/dl       17 - 30 mg/dl       18 - 55 mg/dl         Ortal WBC       / cu mm       M: 6.6 1 million / cu mm       M: 6.6 1 million / cu mm       mg/dl       18 - 55 mg/dl       10 - 200 mg/dl       17 - 30 mg/dl       0 - 200 mg/dl       17 - 30 mg/dl       0 - 200 mg/dl       17 - 30 mg/dl       10 - 200 mg/dl       17 - 30 mg/dl       10 - 200 mg/dl       17 - 30 mg/dl       10 - 20 mg/dl <td>Hasmoglobin       g/dl       M: 14.6 - 17.8 g/dl       File (1) His after flood)       mg/dl       Upto 140 mg/dl         Cotal WBC       / cu mm       4000 - 11000/ cu mm       mg/dl       18.5 - 55 mg/dl       Mc 0.70 - 130 mg/dl         Cotal RBC       mllion / cu mm       M: 45 - 61 mllion / cu mm       mg/dl       0 - 200 mg/dl       Mc 0.70 - 130 mg/dl         Platelet Count       Lokh / cu mm       1.5 - 4.5 Lakh / cu mm       Tridycoride       mg/dl       0 - 200 mg/dl       0 - 200 mg/dl         TI      Min      sea 5 - 10 min       Tridycoride       mg/dl       3.5 - 7.9 mg/dl       0 - 200 mg/dl         VLDL Cholesterol       mg/dl       7 - 32 mg/dl       0 - 25 mg/dl       0 - 25 mg/dl       0 - 25 mg/dl         VLDL Cholesterol       mg/dl       1.5 - 5.7 0 mg/dl       0 - 25 mg/dl<!--</td--><td>cak</td><td>mm AEPH</td><td>and a set of the set o</td><td>(Flood Stater (Pasting)</td><td>y mg/dl</td><td>74 - 130 mg/dl</td></td>	Hasmoglobin       g/dl       M: 14.6 - 17.8 g/dl       File (1) His after flood)       mg/dl       Upto 140 mg/dl         Cotal WBC       / cu mm       4000 - 11000/ cu mm       mg/dl       18.5 - 55 mg/dl       Mc 0.70 - 130 mg/dl         Cotal RBC       mllion / cu mm       M: 45 - 61 mllion / cu mm       mg/dl       0 - 200 mg/dl       Mc 0.70 - 130 mg/dl         Platelet Count       Lokh / cu mm       1.5 - 4.5 Lakh / cu mm       Tridycoride       mg/dl       0 - 200 mg/dl       0 - 200 mg/dl         TI      Min      sea 5 - 10 min       Tridycoride       mg/dl       3.5 - 7.9 mg/dl       0 - 200 mg/dl         VLDL Cholesterol       mg/dl       7 - 32 mg/dl       0 - 25 mg/dl       0 - 25 mg/dl       0 - 25 mg/dl         VLDL Cholesterol       mg/dl       1.5 - 5.7 0 mg/dl       0 - 25 mg/dl </td <td>cak</td> <td>mm AEPH</td> <td>and a set of the set o</td> <td>(Flood Stater (Pasting)</td> <td>y mg/dl</td> <td>74 - 130 mg/dl</td>	cak	mm AEPH	and a set of the set o	(Flood Stater (Pasting)	y mg/dl	74 - 130 mg/dl
Product         Prince         Princ         Princo	Cost         F: 12.1 - 15.9 g/dl         (1) Hrs after food)         mg/dl         18 - 55 mg/dl           Costal WBC         / cu mm         4000 - 11000/ cu mm         mg/dl         16 - 55 mg/dl         Mc. 0.70 - 130 mg/dl           Costal WBC         mg/dl         mg/dl         Mc. 0.70 - 130 mg/dl         Mc. 0.70 - 130 mg/dl           Costal WBC         mg/dl         mg/dl         Mc. 0.70 - 130 mg/dl         Mc. 0.70 - 130 mg/dl           F1 and the first state s	Heamoglobin	ald	CONTRACTOR OF THE OWNER	Blood Sogar (PP)	mg/d!	Upto 140 mg/dl
Data         Import         Import <thimport< th="">         Import         <thimport< th=""> <thimport< th=""></thimport<></thimport<></thimport<>	Data         Image: Image	Zingioun	8.04	F: 12.1 - 15.9 g/dl	(12 Hrs after food)		10 20 - 10
Total RBC       mllion / cu mm       M: 4.6 - 6.1 mllion / cu mm         P1: 3.8 - 5.5 mllion / cu mm       F: 6.6 - 1.1 mg/dl         Plastelot Count       Lakh / cu mm       15 - 4.5 Lakk / cu mm         Tit	Total RBC       milion / cu mm       M: 4.6 - 6.1 milion / cu mm         Platelet Count       Lakh / cu mm       15 - 4.5 Lakh / cu mm         Tital Cholasterol       mg/dl       0 - 200 mg/dl         Tital Cholasterol       mg/dl       35.3 - 7.95 mg/dl         Tital Cholasterol       mg/dl       40 - 160 mg/dl         Tital Cholasterol       mg/dl       35.3 - 7.95 mg/dl         Tital Cholasterol       mg/dl       35.3 - 7.95 mg/dl         Dit Cholasterol       mg/dl       35.3 - 7.95 mg/dl         LDL Cholasterol       mg/dl       35.3 - 7.95 mg/dl         Dit Cholasterol       mg/dl       Million - 0.40 %         Colamophil       %6       2 - 8 %         Dolamophil       %6       2 - 8 %         Diadiset Bilinbhn       mg/dl       40 - 2.2 mg/dl         Mencoviras       %1 - 6 %       Malaine Phosphatase       IUL         Moreal Bilinbhn       mg/dl       32 - 5.3 gl/dl         Milese Liblinbhn       mg	Total WBC	/ cu mm	and the second se	and of a design of the second s		
Non-Net         Initial / G mill         P: 3.8 - 3.5 million / u mm           Platelet Count         Lakh / ou mm         1.5 - 4.5 Lakk / ou mm         Trail Cholenterol         mg/dl         0.9 - 160 mg/dl           Platelet Count         Lakh / ou mm         1.5 - 4.5 Lakk / ou mm         Trail Cholenterol         mg/dl         0.9 - 160 mg/dl           Str	Non-Non-Year III       P: 3.3 + 3.5 million / vu mm       Product Cholestered       mg/dl       0 - 200 mg/dl         Platelet Count       Lakh / cu mm       1.5 - 4.5 Lakh / cu mm       Trigly corride       mg/dl       40 - 160 mg/dl         ST      MinSees       2 - 7 min       Trigly corride       mg/dl       435 3 - 79.5 mg/dl         ST      MinSees       5 - 10 min      MinSees       5 - 10 min       mg/dl       40 - 160 mg/dl         PBS FOR MP       /cu mm       40 - 440 / cu mm      MinSees       5 - 10 min       mg/dl       40 - 350 NUA.         PBS FOR MP       /cu mm       40 - 440 / cu mm      MinSees			and the second sec			F: 0.6 - 1.1 mg/di
Platelet Count       Lakh / au mm       1.5 - 4.5 Lakk / cu mm         3T      MinSecs       2 - 7 min         3T      MinSecs       2 - 7 min         CT      MinSecs       5 - 10 min         AEC       /cu mm       40 - 440 / cu mm         YDL Cholesterol       mg/dl       35 - 79.5 mg/dl         MEC       /cu mm       40 - 440 / cu mm       90 - 160 mg/dl         YDL Cholesterol       mg/dl       40 - 35.0 LUL         SGOT (AST)       I.UL       -35.0 LUL         Sensophil       56       1 - 65 %         Decophil       56       1 - 65 %         CV       56       M: 42 - 52 %         CV       56       M: 42 - 52 %         CV       56       M: 42 - 52 %         MCV       F1.32 - 65 %       Globulin	Platelet Count       Lakh / cu mm       1.5 - 4.5 Lakh / cu mm       ITrgyceride       mg/dl       435 75.5 mg/dl         3T      MinSees       2 - 7 min       mg/dl       135 75.5 mg/dl       110. Cholesterol       mg/dl       135 75.5 mg/dl         CT      MinSees       5 - 10 min       10. Cholesterol       mg/dl       7.32 mg/dl         NEC       /cu mm       40 - 440 / cu mm       500 T (AST)       11.0 - 45.0 RU/d.       -2.4.5.7 mg/dl         YBS FOR MP		include / co min			mg/dl	0-200 mg/dl
BT       Min.       See       2 - 7 min       DL Cholasterol       mg/dl           CT      Min.       See       5 - 10 min	ST      Min       Sees       2-7 min         CT      Min       Sees       5-10 min         AEC       /cu mm       40 - 440 / cu mm       mg/dl       7-32 mg/dl         PBS FOR MP       Ubic Acid       mg/dl       7-32 mg/dl       H3.3-7.7 mg/dl         DYS       /cu mm       40 - 440 / cu mm       SOT (AST)       BUL       0-35.0 BUA         PBS FOR MP       BUC       0-35.0 BUA       0-35.0 BUA       0-35.0 BUA         Volymorph       %6       20 - 40.0 %       Total Bilirobin       mg/dl       0-0.20 BUA         SOPT (ALT)       RUA       0-35.0 BUA       CHL       CHL       0-35.0 BUA         Somophil       %6       2 - 8.7 %       Diversalinable       BUA       0-35.0 BUA         Somophil       %6       1 - 6.7 %       Diversalinable       mg/dl       0-0.2 mg/dl         Somophil       %6       1 - 6.7 %       Diversalinable       mg/dl       6.4 - 8.3 g/dl         CV       %6       M: 42 - 52 %       F: 16 - 64 %       Globalin       g/dl       15 - 5.2 g/dl         MCV       µm3       7.6 - 66 µm3       M/dl       Masol       13 - 5.3 mo/dl       13 - 5.3 mo/dl         MCV       ½	Platelet Count	Lakh / cu mm	the second s			
Min.         Sees         5 - 10 min           ABC         //u mm         40 - 440 / cu mm         mg/dl         Mt 3 - 5 70 mg/dl           ABC         //u mm         40 - 440 / cu mm         SGOT (AST)         U.U. 0 - 35.0 U/L           SGOT (AST)         U.U. 0 - 35.0 U/L         SGOT (AST)         U.U. 0 - 45.0 U/L           PBS FOR MP         SGOT (AST)         U.U. 0 - 45.0 U/L         SGOT (AST)           Objectors         %         20 - 40 %         Alkaline Phosphatase         U.U. ADULT: 53 - 128 RU/L           SGOT (AST)         RUA         -0 - 55.0 U/L         CILL         CILL - 0 - 0.5 U/L           Segobil         %         2 - 8 %         Didencip teal Billinghin         mg/dl         0 - 2.0 mg/dl           Segobil         %         1 - 6 %         Indirect Billinghin         mg/dl         0 - 2.0 mg/dl           Segobil         %         0 - 1 %         Total Protein         g/dl         64 - 4.3 g/dl           CV         %         M: 42 - 52 %         Globulin         g/dl         1 - 5.2 g/dl           CV         %         M: 42 - 52 %         Globulin         g/dl         1 - 5.3 g/dl           MCH         pg for 2 - 32 pg         Globulin         g/dl         1 - 5.3 g/dl         1	ST         Min         Sees         5 · 10 min           ABC         /cu mm         40 · 440 / cu mm         mg/dl         7.32 mg/dl           PBS FOR MP         //cu mm         40 · 440 / cu mm         mg/dl         P:2.4 - 5.7 mg/dl           PBS FOR MP         //cu mm         40 · 440 / cu mm         GOT (AST)         IU.L         0 · 450 IU.L           SOOT (AST)         IU.L         0 · 450 IU.L         0 · 55 · 10 min         P:2.4 - 5.7 mg/dl           SOOT (AST)         IU.L         0 · 450 IU.L         0 · 55 IU.L         0 · 55 IU.L           Somophil         % · 1 · 6 · 75 · 10 min         IU.R         0 · 40 · 96         0 · 0 · 20 mg/dl           Somophil         % · 1 · 6 · 75 · 10 min         IU.L         0 · 0 · 20 mg/dl         0 · 0 · 20 mg/dl           Somophil         % · 1 · 6 · 76 · 10 · 10 · 10 · 10 · 10 · 10 · 10 · 1			The second s	LDL Choicsterol	mg/dl	<130 mg/dl
BC         /cu mm         40 - 440 / cu mm         August in the second	LEC       /cu mm       40 - 440 / cu mm       All of the second secon		the transmission of the second	The second se		mg/dl	7-32 mg/dl
BS FOR MP       SOCT (AST)       RUL       0-35.0 RUL         SOP (AST)       RUL       0-45.0 RUL         Sop (AST)       RUL       0-20.0 RUH         MCV       Sop (AST)       RUL       0.2.0 RUH         MCV       Sop (AST)       RUL       0.2.0 RUH         MCH       PS (AST)       RUL       0.4.60 RUL         MCH       PS (AST)       RUL       1.5.1.5 RUH         MCH       PS (AST)       RUL       1.5.1.5 RUH         MCH       PS (AST)       RUL       1.5.1.5 RUH         MCH	BS FOR MP       BUL       0-35.0 LUL         Olymorph       %       40 - 75 %       SOPT (ALT)       RUR.       0.4 5.0 RUA.         Soprovis       %       20 - 40 %       Rolline Phosphatase       RUL       ADULT: 33 - 128 R         Soprovis       %       20 - 40 %       Rolline Phosphatase       RUL       055 RUA.         Soprovis       %       20 - 40 %       Rolline Phosphatase       RUL       055 RUA.         Soprovis       %       20 - 40 %       Rolline Phosphatase       RUL       055 RUA.         Soprovis       %       20 - 8 %       Rolline Phosphatase       RUL       0.0 - 2.0 mg/dl         Soprovis       %       1 - 6 %       Rolline Phosphatase       RUL       0.0 - 0.2 mg/dl         Soprovis       %       1 - 6 %       Rolline Roline Rolline Rolline Rolline Rolline Roline Rolline Roli				Une Acid	mg/dl	
HS FOR MP       UL       0-450 FU/L         IC       SOPT (ALT)       UL       0-450 FU/L         Volymorph       %       40 - 75 %       CHLT       ABaline Phorphatase       UUL       ADULT: 53 - 128 FU/L         Volymorph       %       20 - 40 %       Control Bilirabin       mg/dl       00 - 20 mg/dl         Gencophil       %       2 - 8 %       Direct Bilirabin       mg/dl       00 - 20 mg/dl         Octor Hight       %       0 - 1 %       Total Bilirabin       mg/dl       0 - 20 mg/dl         Direct Bilirabin       mg/dl       0 - 0.2 mg/dl       0 - 20 mg/dl       13 - 53 g/dl         MCV       %       M: 42 - 52 %       F: 36 - 46 %       Globalin       g/dl       1.5 - 53 g/dl         MCV       µm3       76 - 96 µm3       Adverte Bilirabin       g/dl       1.5 - 53 g/dl       Anviase         MCV       µm3       76 - 96 µm3       Adverte Bilirabin       g/dl       1.5 - 53 g/dl       Anviase       BU/L       2.2 - 80 IU/L         MCV       µm3       76 - 96 µm3       Adverte Bilirabin       g/dl       1.5 - 53 g/dl       Anviase       BU/L       2.2 - 80 IU/L       ACH       2.2 - 80 IU/L       ACH       2.8 - 01/L       So - 05 Mi/L       ACH	SOP F(ALT)       TVL       0-450 H07.         INC       SOPT(ALT)       U/L       0-450 H07.         Volymorph       %       40 - 75 %.       U/L       Abaline Phosphatase       U/L       Abaline Phosphatase         Volymorph       %       40 - 75 %.       U/L       Abaline Phosphatase       U/L       Abaline Phosphatase         Volymorph       %       40 - 75 %.       U/L       0-450 H07.       C/L       Abaline Phosphatase       U/L       0.0 - 20 mg/dl         Somophil       %       1 - 6 %.       Midline Phosphatase       H04.       0.0 - 20 mg/dl       0.0 - 20 mg/dl         Somophil       %       1 - 6 %.       Midline Phosphatase       R/L       0.2 - 0.0 mg/dl         Somophil       %       1 - 6 %.       Midline Phosphatase       R/L       0.2 - 0.0 mg/dl         Indirect Bilinobin       mg/dl       6.4 - 8.3 g/dl       Midline Phosphatase       R/L       0.2 - 0.0 mg/dl         MCV $\mu m 3$ 76 - 96 $\mu m 3$ Midline Phosphatase       R/L       0.2 - 0.0 I1/L         MCV $\mu m 3$ 76 - 96 $\mu m 3$ Midline R/L       13 - 5.3 mmolf.       35 - 5.3 mmolf.         MCV $\mu g 3$ 10 - 35 %       Midline R/L       10 - 0.0 - 0.0		/cu mm	40 - 440 / cu mm	SGOT (AST)	ILVI.	0-35.0 IL/L
Volymorph       %       40 - 75 %       Critical Constraints $ymphosytes$ %       20 - 40 %       Total Bilirubin       mg/d1       0 - 2.0 mg/d1 $doncortes$ %       2 - 8 %       Dimet Bilirubin       mg/d1       0 - 2.0 mg/d1 $doncortes$ %       0 - 1 %       mg/d1       0 - 2.0 mg/d1       Dimet Bilirubin       mg/d1       0 - 2.0 mg/d1 $doncortes$ %       0 - 1 %       mg/d1       0 - 2.0 mg/d1       Dimet Bilirubin       mg/d1       0 - 2.0 mg/d1 $doncortes$ %       0 - 1 %       mg/d1       0 - 2.0 mg/d1       Dimet Bilirubin       mg/d1       0 - 2.0 mg/d1 $doncortes$ %       0 - 1 %       Marce Bilirubin       mg/d1       0 - 2.0 mg/d1       Dimet Bilirubin       mg/d1       0 - 2.0 mg/d1 $doncortes$ %       0 - 35 %       Gidbalin       g/d1       0 - 35 3 g/d1       Marce $dCV$ %       Marce       R/M       Gidbalin       g/d1       0 - 35 3 g/d1       Marce $dCV$ %       Marce       R/M       G/d2       0 - 60 0 U/A       Lipase       U/A       0 - 60 0 U/A $dCV$ %       Marce       0 - 0.0 0 U	Oymorph       %6       40 - 75 %       CTILD::210-:810         ymphosytes       %6       20 - 40 %       Tital Bilirubin       mg/dl       0 - 25 RUA.         denocytes       %6       2 - 8 %       Tital Bilirubin       mg/dl       0 - 2.0 mg/dl         denocytes       %6       0 - 1 %       Tital Bilirubin       mg/dl       0 - 0.2 mg/dl         denocytes       %6       0 - 1 %       Tital Bilirubin       mg/dl       0 - 0.2 mg/dl         denocytes       %6       0 - 1 %       Tital Bilirubin       mg/dl       0 - 0.2 mg/dl         denocytes       %6       0 - 1 %       Tital Bilirubin       mg/dl       0 - 0.2 mg/dl         denocytes       %6       N - 42 - 52 %       Tital Bilirubin       mg/dl       0 - 2.0 mg/dl         denocytes       %6       N - 42 - 52 %       Tital Bilirubin       mg/dl       5 - 53 mg/dl         denocytes       %6       N - 1 - 55       Moltal Bilirubin       mg/dl       5 - 53 mg/dl         delocytes       %6       M - 2 - 52 %       Moltal Bilirubin       mg/dl       3 - 53 mg/dl         delocytes       mg       2 - 7 - 32 pg       Moltal Bilirubin       mg/dl       3 - 53 mg/dl         delocytes       %6 - 10 mg/dl	and the second se			SGPT (ALT)		0-45.0 IU/L
Orymopholy $56$ $20 - 40.95$ Monocytes $56$ $20 - 40.95$ Monocytes $56$ $20 - 40.95$ Monocytes $56$ $20 - 40.95$ Derive Billinghin $mg/dl$ $0.0 - 2.0 mg/dl$ Basebil $56$ $2 - 8.96$ Derive Billinghin $mg/dl$ $0.0 - 2.0 mg/dl$ Basebil $56$ $0 - 155$ CV $56$ $0 - 155$ CV $96$ $M : 42 - 52.96$ $M : 42 - 52.96$ MCV $\mu m3$ $76 - 96 \mu m3$ $Amvlase$ $Bl/dl$ $23 - 5.3.9 dl$ MCH $p.8.2.7.32.pd$ $Bl/dl$ $35 - 5.3.9 dl$ $M = 0.6.0 mg/dl$ MCH $p.8.2.9 dl$ $30 - 35.54$ $M = 0.01 l.l.$ $23 - 5.01 mol.l.$ MCH $p.8.2.9 dl$ $30 - 35.54$ $M = 0.01 l.l.$ $35 - 5.01 mol.l.$ MCH $p.8.2.9 dl$ $30 - 35.54$ $M = 0.01 mol.l.$ $35 - 5.01 mol.l.$ MCH $p.8.2.9 dl$ $M = 0.02 mol.l.$ $M = 0.01 mol.l.$ $35 - 5.01 mol.l.$ MCH $M = 0.0.2 mg/dl$ $M = 0.02 mol.l.$	Ovymopholytes       %       20 - 40 %         Monocytes       %       2 - 8 %         Senisophil       %       2 - 8 %         Senisophil       %       1 - 6 %         Manocytes       %       0 - 1 %         Senisophil       %       0 - 1 %         MCV       µm3       76 - 96 µm3         ACH       p2       27 - 32 pg         ACH       p3       30 - 33 %         DUPTISE       Itipase       RL/L       22 - 80 R/L         MCH       p2       27 - 32 pg       Golduin       g/di       1.5 - 3.5 g/di         MCH       p3       27 - 32 pg       Golduin       mmol/L       35 - 14.5 mmol/L         MCH       p3       10 - 35 %       mmol/L       35 - 13 mmol/L         HCY Test				Alkaline Phosphatase	IUL	
Monocytes       %       2 - 8 %         Oeinoophil       %6       1 - 6 %         Jassophil       %6       1 - 6 %         Jassophil       %6       1 - 6 %         Jassophil       %6       0 - 1 %         CV       %6       1 - 6 %         Jassophil       %6       0 - 1 %         CV       %6       1 - 6 %         Jassophil       %6       0 - 1 %         CV       %6       M - 42 - 52 %         CV       %6       M - 42 - 52 %         MCN       g/dl       53 - 53 g/dl         MCV       µm3       76 - 96 µm3         MCV       µm3       76 - 96 µm3         MCV       µm3       76 - 96 µm3         MCH       pg 2 7 - 32 pg       Sodiam       Rul       0.4 - 20 mg/dl         MCH       pg 2 7 - 32 pg       Sodiam       Namol/L       0.3 - 53 mmol/L         MCH       pg 2 7 - 32 pg       Sodiam       mmol/L       0.4 - 10 mmol/L         MCH       pg 2 7 - 32 pg       Sodiam       Mamol/L       95 - 145 mmol/L         MCH       gd	Monocytes       %6       2 - 8 %         Derest Billmahin       mg/di       0.0 - 2.0 mg/di         Sassphil       %6       1 - 6 %         Direct Billmahin       mg/di       0.0 - 2.0 mg/di         Direct Billmahin       g/di       0.2 - 2.0 mg/di         CV       %6       1 - 6 5%         Albuminin       g/di       1.5 - 3.5 g/di         Albuminin       g/di       1.5 - 3.5 g/di         Albuminin       g/di       1.5 - 3.5 g/di         Lipase       BU/L       2.2 - 80 B/di         MCH       pg       27 - 32 pg         Sodium       McH       g.2 - 3.5 mmol/L         Bit       Direct Bilmahin       g/di       1.3 - 5.5 g/di         HIV 1 & 2 Test       Lipase       BU/L       2.0 - 6.0 B/di         HBX Ag Test				OGT	IUAL	
Sectionophil       %       1 - 6 %       Different Suffragen       magedit       0.2 - 0.3 mg/dt         Sectionophil       %       0 - 1 %5       magedit       0.2 - 0.3 mg/dt       0.2 - 0.3 mg/dt         Sectionophil       %       0 - 1 %5       magedit       0.2 - 0.3 mg/dt       0.2 - 0.3 mg/dt         Sectionophil       %       0 - 1 %5       magedit       0.2 - 0.3 mg/dt       0.2 - 0.3 mg/dt         Sectionophil       %       0 - 1 %5       magedit       0.2 - 0.3 mg/dt       0.2 - 0.3 mg/dt         MCW       #101 % 12 % 16 %       %       1.6 % 6 %       Milliwish       magedit       0.2 - 0.3 mg/dt         MCW       #101 % 12 % 16 %       %       1.5 % 14 %       1.5 % 14 %       1.5 % 14 %         MCH       pg       27 - 32 pg       Milliwish       mmold.       135 + 14 % mmold.         MCH       pg       27 - 32 pg       Sodiam       Mam/lase       RUA.       2.8 o RUA.         MCH       pg       27 - 32 pg       Sodiam       Mon/lase       RUA.       2.5 - 5.5 mmol/L.         HUY 16 % 17 % 11 % 15 % 12 %       10 - 35 %       mmol/lase % 10 % mmol/L.       135 + 14 % mmol/L.       136 + 14 % mmol/L.       136 + 14 % mmol/L.         HUY 16 % 17 % 11 % 16 % 12 % mmol/L	Sectionsphil       96       1 - 6 %         Saccobil       54       0 - 1 %         Saccobil       64       8.3 g/dl         MCW       mm3       76 - 96 µm3         MCH       92       27 - 32 pg         MCH       92       27 - 32 pg         Sodium (Na)       mmool.       135 - 14 % mool.         MCH       92       27 - 32 pg         Sodium (Na)       mmool.       135 - 14 % mool.         HCV       4CHC       %       10 - 6.0 mg/dl         HIV 1 & 2 Test	Annocytes					
Seaccons $90$ $0 - 179$ CV $96$ M: 42 - 52 $96$ Total Protein $g/dl$ $6.4 - 8.3 g/dl$ MCV $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ MCV $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ MCV $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ MCV $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ MCV $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ $g/dl$ $3.5 - 5.2 g/dl$ MCH $ps$ $27 - 32 pg$ $g/dl$ $3.5 - 5.3 g/dl$ $MCL$ $22 - 80 10/n$ $MCL$ MCH $ps$ $27 - 32 pg$ $30 - 35 \%$ $Moldle       Moldle $	Seascond       74       0 - 1.75         CV       %       M: 42 - 52 %       F: 36 - 46 %         Albumin       g/dl       3.5 - 5.3 g/dl         Albumin       g/dl       1.5 - 3.5 g/dl         Albumin       g/dl       6.4 - 8.3 g/dl         Albumin       g/dl       1.5 - 3.5 g/dl         Albumin       g/dl       6.4 - 8.3 g/dl         Albumin       g/dl       1.5 - 3.5 g/dl         Albumin       g/dl       1.5 - 3.5 g/dl         MCH       p3       27 - 32 pg         MCH       p3       27 - 32 pg         MCH       p3       27 - 32 pg         MCH       p3       27 - 35 mmol/L         Hit's & 2 Test       Immol/L       98 - 107 mmol/L         Hac'       g/dl       8.6 - 10.2 mg/dl       8.6 - 10.2 mg/dl         ASO Titre       0 - 20.0 IU/ml       RD       RD       RD         ASO Titre       0 - 20.0 IU/ml       RD       RD       RD       RD         Typhi Dot ig G       M       M       M </td <td>losinophil</td> <td></td> <td></td> <td></td> <td></td> <td></td>	losinophil					
MCV $\mu$ m3       76-96 µm3 $\mu$ m3       76-96 µm3         MCH       pg       27-32 pg       RUA.       Q.2-80 IUA.         MCH       pg       27-32 pg       RUA.       Q.0-60.0 IUA.         MCH       96       30-35 %       Bodkum (Na)       mmold.       135-145 m mold.         MCH       96       30-35 %       Bodkum (Na)       mmold.       35-53 m mold.         MCH       96       30-35 %       Bodkum (Na)       mmold.       35-53 m mold.         MIV1 & 2 Test	F: 36 - 46 %       Giobulin $pdit$ (.5 - 3.5 g/d)         MCV $\mu$ m3       76 - 96 $\mu$ m3       Lipuse       RUA.       22 - 80 LVA.         MCH $pg$ 27 - 32 $pg$ Lipuse       RUA.       0.0 - 60.0 RUA.         MCH $\eta g$ $30 - 35 \%$ Distance       RUA.       23 - 95 mmol/L.         MCH $\eta g$ $30 - 35 \%$ mmol/L.       35 - 107 mmol/L.       35 - 107 mmol/L.         MCV test $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ HBA Ag Test $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ HCV test $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ $\dots$ VDRL/TPHA Test $\dots$	Basophil	%	0-1%	Total Protein		
MCV       urn3       76 - 96 um3       Amylase       RUL       22 - 80 KM         MCH       ps       27 - 32 ps       Sodium       Nucl. 0.0 - 60.0 TUL       Mucl. 135 - 53 mmol/L         MCH       %       30 - 35 %       Sodium       mmol/L       135 - 53 mmol/L         MITTES       Sodium       Namel/L       35 - 53 mmol/L       Sodium       Num         HIV 1 & 2 Test       Sodium       Num       Mucl. 135 - 53 mmol/L       Sodium       Sodium       Num         HBa Ag Test       Sodium       Chlorido       Clip mmol/L       38 - 102 mg/dl       Sodium         HCV Test       Sodium       0 - 200 IU/mil       Rec       Sodium	MCV       um3       76 - 96 un3       Amvinse       RUL       22 - 80 H/L         MCH       pg       27 - 32 pg       Rule       Rule       0.6 - 60.0 H/L         MCH       %       30 - 35 %       Bodiam       mmol/L       98 - 107 mmol/L         DEFTES       Introduction       %       30 - 35 %       Bodiam       mmol/L       35 - 145 mmol/L         HIV 1 & 2 Test       Introduction       Sodiam       mmol/L       35 - 145 mmol/L       35 - 102 mg/dl         HEX Ag Test       Introduction       Introductio	CV	96			g/dl	3.5 - 5.2 g/dl
MCH       pg       27 - 32 pg         MCH       pg       27 - 32 pg         MCHC       %       30 - 35 %         Sodium       mmol/L       135 - 145 mmol/L         Sodium       mmol/L       135 - 145 mmol/L         MCH       0.0 - 60.0 IU/L       Sodium         MCH       %       30 - 35 %       Poinssium (Na)       mmol/L       135 - 145 mmol/L         MIN       Sodium       Manual (Na)       mmol/L       135 - 145 mmol/L       Iso mol/L         HBA g Test       Poinssium (K)       mmol/L       135 - 145 mmol/L       Iso mol/L       Iso mol/L         HCV Test       Immol/L       0.7 00 IU/mil       Sec       Immol/L       Iso mol/L       Iso mol/L         ASO Titre       Immol/L       0.2 00 IU/mil       ABO       Ref       Immol/L       Iso mol/L       Immol/L         Ch2       BA       One of the sec       Immol/L	MCH       pg       27 · 32 pg         MCHC       %       30 · 35 %         MCHC       %       mmol/L       35 · 143 m mol/L         HBs Ag Test	1791					
4CHC       %       10 - 35 %       Sodium (Na)       mmol/L       135 - 145 mmol/L         111/1185       H1V 1 & 2 T rest	ACHC       %       30 - 35 %       Sodium       mmol/L       135 - 145 m mol/L       135 - 145 m mol/L         DITTES       HIV 1 & 2 Test		and the second s				
HIV 1 & 2 Test	HIV 1 & 2 Test		96				
HIV 1 & 2 1 fest       Image: Ca2+ mg/dl       8.6-10.2 mg/dl         HBs Ag Test       Image: Ca2+ mg/dl       8.6-10.2 mg/dl         HCV Test       Image: Ca2+ mg/dl       8.6-10.2 mg/dl         JCV Test       Image: Ca2+ mg/dl       8.6-10.2 mg/dl         ASO Titre       Image: Ca2+ mg/dl       8.6-10.2 mg/dl         Rh       Image: Ca2+ mg/dl       8.6-10.2 mg/dl         PF & PV Aatigen Test       Image: Ca2+ mg/dl       1.06-1.81 ng/mL         Typhi Dot 1g M       Image: Ca2+ mg/dl       71 mg/mL       0.35-5.50 µlU/mL         Ig G       Image: Ca2+ mg/dl       Image: Ca2+ mg/dl       0.35-5.50 µlU/mL       1.23-4.2 pg/mL         Ig M       Image: Ca2+ mg/dl       Image: Ca2+ mg/dl       1.23-4.2 pg/mL       1.23-4.2 pg/mL         Ig M       Image: Ca2+ mg/dl       Image: Ca2+ mg/dl       1.3-6.2 mg/dl       1.3-6.2 mg/dl         Ig M       Image: Ca2+ mg/dl       Image: Ca2+ mg/dl <td< td=""><td>HIV 1 &amp; 2 Test      </td><td>the second s</td><td></td><td></td><td>Potassium (K)</td><td></td><td></td></td<>	HIV 1 & 2 Test	the second s			Potassium (K)		
HCV Test	HCV Test					mg/dl	86-10.2 mg/dl
VDRL/TPHA Test	VDRL/TPHA Test	HCV Test	· · · · · · · · · · · · · · · · · · ·			0.50	
ABO         CRP       0-200 fU/ml         RA factor       0-200 fU/ml         PF & PV Antigen Test       0-200 fU/ml         Typhi Dot 1g M       11         Ig G       124 gyml         Ig G       11         NS, Ag       11         Ig G       11         Ig G       11         Widal Test (Tube/Silde Method)       11         ITTRE I 120 I 1:40       1:80         HP       11         AF"       120 I 1:40         BH*       120 I 1:40		VDRL/TPH			INR	Acc	
RA factor       0-20.0 IU/ml $\overrightarrow{13}$ ng/ml       0.6-1.81 ng/ml         PF & PV Aatigea Test       1       ug/ml       5.01-12.45 µg/ml         Typhi Dot Ig M       1       1       1       0.85-5.50 µlU/ml       0.35-5.50 µlU/ml         Ig G       1       1       1       0.89-1.76 ng/dl       0.35-5.50 µlU/ml       1         Dengue Test       1       1       1       0.89-1.76 ng/dl       1         NS, Ag       1       1       1       10.89-1.76 ng/dl       1         Ig G       1       1       1       1       1       1         Ig G       1       1       1       1       1       1       1         Widal Test (Tabe/Silde Method)       1	RA factor       0-20.0 IU/ml       T3       ng/mL       0.6-1.81 ng/ml         PF & PV Aatigea Test       174       ug/mL       5.01 - 12.45 µg/mL         Typhi Dot lg M       174       ug/mL       0.35 - 5.50 µlU/mL         Ig G       174       ug/mL       0.335 - 5.50 µlU/mL         Dengue Test       174       ug/mL       0.335 - 5.50 µlU/mL         NS, Ag       186       174       ng/dL       0.389 - 1.76 ng/dL         Ig M       196       1160       1180       1160       1180         Widal Test (Tabe / Silde Method)       1160       11320       MONTOUX TEST (\$ T.U./10 T.U.)         TTRE       120       1140       1180       1160       11320         Off       180       1160       11320       MONTOUX TEST (\$ T.U./10 T.U.)         HP*       180       1160       11320       MONTOUX TEST (\$ T.U./10 T.U.)         HP*       180       1160       11320       MONTOUX TEST (\$ T.U./10 T.U.)				ABO		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	PF & PV Antigen Test:       T4       ug/ml.       5.01 - 12.45 µg/ml.         Typhi Dot Ig M       Ig G       Ig G       0.35 - 5.50 µlU/ml.       0.35 - 5.50 µlU/ml.         Ig G       Ig G       PT3       pg/ml.       2.3 - 4.2 pg/ml.         Ig M       Ig G       Ig G       NS, Ag       Normal < 5.7%					namL	0.6-1.81 nm/mL
Ig G       PT3       pg/mL       2.3 - 4.2 pg/mL         Dengue Test       NS, Ag       ng/dL       0.89 - 1.76 ng/dL         Ig M       Ig G       HbAle Test       %       Pre Diabetes 3.7 - 6.4%         Ig G       Ig G       MONTOUX TEST (5 T.U/10 T.U.)       MONTOUX TEST (5 T.U/10 T.U.)         Widal Test (Tube / Slide Method)       MONTOUX TEST (5 T.U/10 T.U.)       MONTOUX TEST (5 T.U/10 T.U.)         IT RE 1:20 11:40 11:80 11:160 11:320       MONTOUX TEST (5 T.U/10 T.U.)       MONTOUX TEST (5 T.U/10 T.U.)         HP*       Image: Content of the second secon	Ig G       PT3       pg/mL       2.3 - 4.2 pg/mL         Dengue Test       NS, Ag       ng/dL       0.39 - 1.76 ng/dL       0.39 - 1.76 ng/dL         NS, Ag       Ig M       Ig M       Normal < 5.7%					and the second se	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	and the second se		/		pg/mL	
Ig M       Ig G       Pre Diabetes $5.7-6.4\%$ Ig G       Ig G       Ig G       Ig G         Widal Test (Tube / Slide Method)       Ig G       Ig G       Ig G         If TRE 1:20 11:40 11:80 11:160 11:320       If G       Ig G       Ig G         If Head Test (Tube / Slide Method)       If G       Ig G       Ig G       Ig G         If TRE 1:20 11:40 11:80 11:160 11:320       If G       Ig G       Ig G       Ig G       Ig G         If Head Test (Tube / Slide Method)       If G       Ig G <td>Ig M       Ig G       Pre Diabetes <math>5.7-6</math>         Ig G       Image: State of the state o</td> <td></td> <td></td> <td>/</td> <td>114</td> <td>. agrat.</td> <td>Normal &lt; 5.7%</td>	Ig M       Ig G       Pre Diabetes $5.7-6$ Ig G       Image: State of the state o			/	114	. agrat.	Normal < 5.7%
Widal Test (Tabe/Silde Method)       MONTOUX TEST (ST.U.10T.U.) $TTRE 1:20$ 1:40 1:80 1:160 1:320       Image: Construction of the second seco	Widal Test (Tabe/Silde Method)       :       MONTOUX TEST (\$ T.U.10 T.U.) $TTRE 1:20$ 1:40 1:80 1:160 1:320       * $F_{ernst}m - 626$ $P - 70$ $H^{*}$	1	g M :		HbA1c Test	- 96	Pre Diabetes 5.7-6.4%
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $		gG :				Diabetes > 0.3%
AH" Good P-70	AH" BH"				MONTOUX TEST (5)	CU/10 T.U.)	
H" BH"	H" HH" BH"		1:40 1:80	1:160 1:320	* Cita		0
BH"	BH"		+ + +		" rentritin-	- 6206	1-20
BR*	BR*		++++				
TES STUDY:	'BS STUDY :	BH*					
1		BSSTUDY					
1							71
1		8 K			•		
1		107					1 No.
1							
Λ.							
	Λ.						

Kegd: No		5282	TTAL, BELTOI REPORT (Dept. FORM - A		761012
Patient Nam	· Bin	ta T	alukdar	Dat	e <u> </u>
Ins. No	RFITI	n/	No.		3.8 Sex -
	MANDEOG	Hospt	No	Bed No	
TEST	FINDINGS	NORMAL RAN	and the second s	AND THE REPORT OF	A6-14-5-16-16-16-16-16-16-16-16-16-16-16-16-16-
ESR	mm AEFF	M:0-10 mm	Blood Sugar (Random	FINDINGS	NORMAL RANG
Heamoglobia		F : 0 - 20 mm	Blood Sugar (Pasting)	mg/d	74-110 ma/dl
	B/d	M : 14.6 - 17.8 g/dl F : 12.1 - 15.9 g/dl	Blood Sugar (PP) (12 Hrs after flood)	mg/d	Upto 140 mg/dl
Total WBC	/ cu mm	4000 - 11000/ cu mm	Creatinine		18-55 mg/dl
Total RBC		M:4.6-6.1 milion/cu	ann -	mg/di	P:0.6-1.1 maidi
Platelet Count		F: 3.8 - 5.5 million / ou	nam Total Cholasterol	mg/dl	0-200 mg/dl
BT I		1.5 - 4.5 Laich / cu mun	- HDL Choistard	mg/dl	40 - 160 mg/di 35.3 - 79.5 mg/di
T		2-7 min	LDL Choiesterol VLDL Choiesterol	ib/em	1 <130 mm/di
ABC		5-10 min	Utic Acid	mg/di mg/di	7-32 mg/di M: 3.5 - 7.0 mg/di
BS FOR MP	/cu mm	40 - 440 / cu mm	SGOT (AST)	4	P:24-57mold
DO FOR ME		/	SGPT (ALT)	111/1	0-33.0 RU/L 0-45.0 RU/L
olymorph		/	Alkaline Phosphatas	e IUL	ADULT: 53 - 128 ILM.
ymphocytes	- % %	40 - 75 %	007	117	CHILD:210-810 TIM
denocytes esinophil	. 36	2-8%	Total Bilirubia	mg/dl	0-55 IU/L 0.0-2.0 mg/dl
tsophil	%	1-6%	Direct Bilirabin	. mg/dl	0-0.2 me/di : )
V I	%	M: 42 - 52 %	Total Protein	g/dt	9.2-0.8 mm/til 6.4-8.3 g/dl
CV		F: 36 - 46 %	Albumin Globulia	g/di	3.5-5.2 g/dl
CH	Emu and	76 - 96 µm3	Amylase	EUL EUL	1.3-3.5 g/dl 22-80 IU/L
CHC	PA %	27 - 32 pg 30 - 35 %	Lipase Sodium (Na)	IUL	0.0-60.011/1
UNN A AN		- day	Potassium (K)	mmol/L	135-145 m moVL 33-53 m moVL
HIV 1 & 2 Test HBs Ag Test	-		Chloride (CI)	mmol/L	93-107 m mol/L
HCV Test	ł		P. Time (1)	mg/di j	8.6-10.2 mg/dl
VDRL/TPHA T		C 000 1	(C) INIR	800	
CRP	:	0-200 IU/m 0-6.0 mg/dl	ABO		
RA factor	:	0 00.0	73	nated	0.6 - 1.81 ng/mL
Typhi Dot' Ig M	1		74	µg/ml.	5.01 - 12.45 up/mT.
Ig G Dengue Test	1		TSH FT3	S'9 HUML	0.35-5.50 WILLAML
· NS,Ag	·	/	FT4	ng/dL	2.3 - 4.2 pg/mL 0.89 - 1.76 ng/dL
Ig M Ig O	!		HbAle Test	96 F	Normal <3.7% Pre Diabetes 3.7 - 6,4% Diabetes > 6.5%
Idal Tast (Tabe	/Slide Method)	•	MONTOUX TEST (ST.	U/IOTU)	0.3%
31 1:20 11:4	40 1:80 1:1	60 1:320			
			5 m *		
			2 C.		
					· •
					8
					12 120
	*U				

Regd: No	2689	the stand water	ORM - A	Date	22/5/24
Patient Name	Nika	nala si	nha	Ane	Lton E
Las. No	0	17. Hospt. No	and the state of the	Red No.	
HA		ICAL TEST		IO-CHEMICA	Ward No.
	FINDINGS	NORMAL RANGE	TEST	FINDINGS	
ESR	mm AEFH	M:0-10 mm F:0-20 mm	Blood Sugar (Random)	mg/dl	74-150 mg/dl
Heamoglobin	eldi	M: 14.6 - 17.8 g/dl	Blood Sugar (Fasting) Blood Sugar (PP)	mg/dl mg/dl	74 - 110 mg/dl
and a second	Bai	F : 12.1 - 15.9 g/dl	(12 Hrs after food)		
Total WBC	/ cu mm	4000 - 11000/ cu mm	Creatinine		18 - 55 mg/di
Total RBC		M:4.6-6.1 million/cumm		mg/dl	M: 0.70 - 1.30 mg/dl F: 0.6 - 1.1 mg/dl
11-1	Contraction of the	F: 3.8 - 5.5 million / cu mm	Total Cholesterol Triglyceride		0-200 mg/di
latelet Count	Lakh / cu mm	1.5 - 4.5 Lakh / cu mm .	HDL Cholesterol		40 - 160 mg/dl
π		2-7 min	LDL Cholesterol		35.3 - 79.5 mg/dl <130 mg/dl
T	Min Secs	5-10min	VLDL Choiesterol	mg/dl	7-32 mg/dl
EC			Uric Acid	mg/dl	M: 3.5 - 7.0 mg/dl
BS FOR MP	/cu.mm	40 - 440 / cu mm	SGOT (AST)	6	F: 2.4 - 5.7 mg/dl
	- 12 x50	Station of the second	SGPT(ALT)	IUL	0-35.0 JU/L 0-45.0 H/L
LC	4 - 01		Alkaline Phosphatase	- IUIL	ADULT:53-128 FUAL
olymorph	%	40 - 75 %	-		CHILD: 210-810 IU/L
ymphocytes fonocytes	%	20 - 40 %	OGT Total Bilirubin	IUL	0-55 TU/L
osinophil	%	2-8%	Direct Bilirubin	<ul> <li>mg/dl</li> </ul>	0.0 - 2.0 mg/dl
asophil	%	1-6%	Indirect Bilirubin		0-0.2 mg/dl 0.2-0.8 mg/dl
CV I			Total Protein	g/dl	6.4 - 8.3 g/dl
09:10.	96	M: 42 - 52 %	Albumin	g/dl	3.5 - 5.2 g/di
ICV.	jum3	F: 36 - 46 %	Globulin	g/dl	1.5-3.5 g/dl
ICH .	PB	76 - 96 µm3 27 - 32 pg	Amylase -		22-80 TU/L
ICHC -	96	- 30 - 35 %	Socium (Na)	IU/L mmol/L	
THERS		Ban La La	Potassium (K)		3.5-5.3 m mol/L
HIV & 2 Test	C. 3		Chloride (CI)	mmol/L	98 - 107 m mol/L
HBs Ag Test	:		Ca2+ P. Time (T)	mg/dl	86 - 10.2 mg/dl
HCV Test			P. Time (T) (C)	sec	The second s
ASO Titre			INR	sec	and the second second second
CRP			ABO	1. N	CRASH SHIT
RA factor		0-200 II I/ml	Rh · · · · · · · · · · · · · · · · · · ·		The state of the
PF& PV Antig	en Test :		T4 .	ng/mL	0.6-1.81 ng/mL
Typhi Dot Ig M				µg/mL Э. ₽ 6 µIU/mL	5.01 - 12.45 µg/mL 0.35 - 5.50 µRL/mL
Ig G Dengue Test			FT3	pg/mL	23-42 pg/mL
	1	/.	FT4	ng/dL	0.89 - 1.76 ng/dL
		14	Hh & Is Test		Normal < 5.7%
Ig G			rivale lest		
Widal Test (Tub TRE 1:20 1 7 7 19 19 19 19 19 19 19 19 19 19 19 19 19	e/Siide Method) 240 1:80 1:	160 1:320	MONTOUX TEST (5 T.	UJOTU.)	
STUDY:					A Lot Inter
	Cart Marshall	2.40 2.2			125.
and the second					Contraction of the
Widal Test (Tub <u>TRE</u> 1:20 1 " 	e / Slide Method).		HbAlc Test MONTOUX TEST (5 T.	%	Normal <5.7% Pre Diabetes 5.7 - 6. Diabetes > 6.5%

Patient Nam	. Nirn	81 FO	inha	Age (	14 sm F
Ins. No	DIIT		1	Bed No.	Ward No.
110, 110, 1111	AFMATOLOGI	CALIEST		Det HEATE A	
TEST		NORMAL RANGE	TEST		NORMAL RANGE
ESR		M:0-10 mm	Blood Super (Random)	mg/di	74-150 mg/dl
leamoglobin	g/dl	F : 0 - 20 mm M : 14.6 - 17.8 g/dl	Blood Sugar (Pasting) Blood Sugar (PP)		74-110 mg/dl Upto 140 mg/dl
		F : 12.1 - 15.9 g/dl	(17 Hrs after food) Unve	me/dl	18-55 mg/dl
lotal WBC	/ cu mm		Creatinine	mg/di	M: 0.70 - 1.30 mg/dt
Iotal RBC	million / cu mm	M:4.6-6.1 milion/cu.mm F:3.8-5.5 milion/cu.mm	Total Cholesterol	mg/dl	P: 0.6 - 1.1 mg/df 0-200 mg/dl
Intelet Count	Lakh / cu mm	1.5 - 4.5 Lakh/ cu mm	Trigiyceride HDL Cholesterol	mg/dl	40 - 160 mg/dl 35.3 - 79.5 mg/dl
T	the second s	2-7 min	LDL Choiesterol	mard	<130 mg/dl
T	The second s	5 - 10 min	VLDL Cholesterol Uric Acid	mg/dl	7-32 mg/di M: 3.5 - 7.0 mg/di
ABC	' /cu mm	40 - 440 / cu mm			P.2.4-5.7 mg/dl
BS FOR MP			SGOT (AST) SGPT (ALT)	IUL.	0-35.0 R.M.
al.C		•	Alkaline Phosphatase	INL	ADULT: 53 - 128 IU/L
olymorph	. %		GGT	11/1	CHILD:210-810 IL/L 0-55 IL/L
amphocytes denocytes	**		Total Bilirubio	mg/dl	0.0-2.0 mg/dl
ioninophil	%	1-6%	Direct Bilirabia	. mg/dl	0-0.2 mg/di ' '
Integration	*		Total Protein	a di	64-83 gtdl
CV .	%	M: 42 - 52 % F: 36 - 46 %	Albamin Giobulia		33-52 g/d 13-33 g/d
4CV	Lanu .	76 - 96 µm3	Amviase	IUIL	22-80 IU/L
ACHC	<u>P8</u>	27 - 32 pg 30 - 35 %	Lipuse Sodium (Na)		0.0-60.0 ILVL
TURKS			Potassham (K) Chloride (Cl)	mmol/L	3.3-5.3 mmol/L
HIV1&2			Catonee (Ca)	m movi.	98-107 mmol/L 8.6-10.2 mg/dl
BCV Test	1		P. Time (1) (C)	860	
ASO Three		0-200 IU/ml	INR		
CRP	:	0-6.0 mg/dl	ABO		
RA factor	tigen Test :		73 74		0.6-1.81 ng/mL
Typhi Dot			288	9.27 million	5.01 - 12.45 µg/ml. 0.35 - 5.50 µll.l/ml.
Deugue Ter	[gG :	/	FIS	pg/mL	23-42 pg/mL
	Ag · :		FT4	ng/dL	0.89 - 1.76 ng/dL Normal < 5,794
	8M :		HhAle Test	*	Pre Diabetes 5,7-6,4% Diabetes > 6,5%
Widai Teet TIRE 1:20 O" H" AH" BH"	Tabe/Silde Method)	Contraction of the local division of the loc	MONTOUXTEST (ST * Feturiti		)
BS STUDY :					

FINDINGS	Hospt. No.		Age	Sex
FINDINGS				
FINDINGS	CALTEST			
	NORMAL RANGE		FINDINGS	NORMAL RANGE
And A COURSE AND A	M:0-10 mm	TEST Blood Sugar (Random)	mg/dl	74 - 150 mg/dl
and the second se	F : 0 - 20 mm	Blood Sugar (Fasting)	mg/dl mg/dl	74 - 110 mg/dl Upto 140 mg/dl
g/d1	M : 14.6 - 17.8 g/dl	Blood Sugar (PP) (12 Hrs after food)	mgyat	
and straight the	F: 12.1 - 15.9 g/dl	Uma	mg/dl	18-55 mg/dl
And and an other statements	4000 - 11000/ cu mm	Creatining	mg/dl	M: 0.70 - 1.30 mg/dl F: 0.6 - L.1.mg/dl
millon / cu mm		Total Cholesterol		0-200 mg/dl
	and the second se	Triglyceride		40 - 160 mg/dt 35.3 - 79.5 mg/dt
and the second s	Contraction of the local division of the loc		mg/dl	<130 mg/dl
	Contra Contraction	VLDL Cholesterol	mg/dl	7-32 mg/dl
		Uric Acid	mg/dl	M: 3.5 - 7.0 mg/dl F: 2.4 - 5.7 mg/dl
/cu mm	40 - 440 / cu mm	SGOT (AST)	IUAL	0-35.0 IL/L
		SGPT (ALT)	IU/L	0- 45.0 IU/L ADULT: 53- 128 IU/L
		Alkaline Phosphatase	IUIL	CHILD:210-810 TU/L
		GCT	IUL	0-55 IU/L
		Total Bilirobin	mg/di	0.0 - 2.0 mg/di 0 - 0.2 mg/di
			eng/dl	0.2-0.8 mg/d!
54	Area and a second a	Total Protein	g/dl	6.4-8.3 g/dl
- Stand and M			p/di	15-3.5 16
um3		Amylase	RU/L	22-80 TU/L
28	27 - 32 pg			0.0-60.0 IU/L 135-145 m mol/L
%	30 - 35 %		mmol/L	3.5-5.3 m mol/L
		Chloride (CI)		98-107 m mol/L
			mg/di sec	8.6-10.2 mg/di
2		(C)	sec	
A Test :	0-200 IU/ml	INR		
-	0 - 6.0 mg/dl	Rh		
1	0-20.0 IU/ml	13	ng/mL	0.6 - 1.81 ng/mL 5.01 - 12.45 µg/mL
			Juil/mL	0.35-5.50 µIU/mL
		FT3	pg/mL	2.3-4.2 pg/mL
at .	/	FT4	ng/dL	Normal < 5.7%
ig M :		HbAlc Test	%	Pre Diabetes 5.7-6.4% Diabetes > 6.5%
lg G :	· · · · · ·	MONTOUX TEST (	T.U/10T.U.)	Caller and the second
(Tube / Silde Metho	d) :		and brinking	
1:40 1:80	1:100 1:320	Sealer united	and the second	
-		10, 10, 10, 10, 10, 10, 10, 10, 10, 10,		Contract of Contraction And
	Lakh / cu mm Min Secs Min Secs /cu mm 96 96 96 96 96 96 96 96 96 96	Min         Secs         5 - 10 min           /cu mm         40 - 440 / cu mm           96         40 - 75 %           96         20 - 40 %           96         2 - 8 %           96         1 - 6 %           96         0 - 1 %           96         0 - 1 %           96         0 - 1 %           96         0 - 1 %           96         0 - 1 %           97         36 - 46 %           100         1 - 6 %           100         27 - 32 pg           %         30 - 35 %	F: 3.8 - 5.5 million / cu mm         Lakh / cu mm         Min       Seca         Min       Seca         Min       Seca         /cu mm       40 - 440 / cu mm         /cu mm       40 - 440 / cu mm         /cu mm       40 - 440 / cu mm         SCOT (AST)         SCOT (AST)	F: 3.8 - 5.5 million / cu mm         Jordat Contestation         mg/dt           Lakh / cu mm         1.5 - 4.5 Lakh / cu mm         Triglyceristic         mg/dt           Min         Secs 2 - 7 min         UDL Cholesterol         mg/dt           Min         Secs 5 - 10 min         mg/dt         mg/dt           /cu mm         40 - 440 / cu mm         SGOT (AST)         RUA.           %         20 - 40 %         SGOT (AST)         RUA.           %         20 - 80 %         Direct Bilirobin         mg/dt           %         20 - 40 %         Total Bilirobin         mg/dt           %         20 - 80 %         Direct Bilirobin         mg/dt           %         20 - 1 %         Total Protein         gridt           %         30 - 35 %         Fold Silenobin         mg/dt           mol All section         gridt         Minum         gridt           %         30 - 35 %         Fold Silenobin         mm/dt           %         0 - 200 IU/ml         Sodium (Na)         mmol/L           _cold Silenobin         mg/dt         Minum         gridt           %         0 - 200 IU/ml         Fold Silenobin         gridt           _moviase         III/m         Fold

#### Conclusion

The chosen homoeopathic remedies were very effective in all cases in this series; the patients reported reduction of TSH levels along with improved general well-being and the existing particular symptoms along with management of proper diet and regimen. Further, study is suggested for evaluating a larger spectrum of remedies in treating cases of hypothyroidism.

## Reference

- https://www.mayoclinic.org/diseasesconditions/hypothyroidism/symptoms-causes/syc-20350284#:~:text=The%20thyroid%20is%20a%20smal l,body%20uses%20fats%20and%20carbohydrates.Hyp othyroidism happens when the thyroid gland doesn't make enough hormones.
- https://www.uclahealth.org/medicalservices/surgery/endocrine-surgery/patientresources/patient-education/endocrine-surgeryencyclopedia/tshtest#:~:text=Normal%20Values%3A,very%20closely% 20by%20a%20doctor.
- Khamrui S, Basu T, Sengupta M. Effect of Homoeopathic Medicine on Hypothyroidism-A Case Study. Advancements in Homoeopathic Research. 2018;3(1):47-51.
- Ray AS, Ganguly S, Mukherjee SK, Hazra P, Dutta S, Nath A *et al.* Homoeopathic treatment in hypothyroidism - An open-label, prospective, singlearm, clinical trial. Homeopathic Links. 2021;34(03):191-198.
- 5. James Tyler Kent. Lectures on Homoeopathic Materia Medica, Bjain Publishers (P) Ltd., Second Rearranged Edition; c2009, 1030.
- Farrington EA. MD, Lectures on clinical materia medica in family order, Bjain Publishers (P) Ltd., Fourth Edition Revised and Enlarged, Edition; c2002, 1037.
- 7. Robin Murphy. Lotus materia medica, B Jain Publishers (P) Ltd., Third Edition; c2012.

#### How to Cite This Article

Bhagawati M, Dutta M. Efficacy of *Fucus vesiculosus* Q & thyroidinum 3x in treatment of hypothyroidism. International Journal of Homoeopathic Sciences. 2024;8(2):560-573.

#### Creative Commons (CC) License

This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.